Covalent drugs represent a transformative advancement in medicine, offering unprecedented therapeutic efficacy by forming stable, irreversible bonds with their biological…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
Eli Lilly has ascended to the pinnacle of the pharmaceutical industry, claiming the top spot in the prestigious Pharma 50…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
SEATTLE, WA – Amazon Web Services (AWS) has unveiled Amazon Bio Discovery, a groundbreaking application poised to dramatically accelerate drug…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, has cemented a landmark global research and development…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced an…
Read More
Small Study Suggests Probiotic Yogurt Strain May Boost Immunotherapy Response in Lung Cancer
The landscape of lung cancer treatment has undergone a significant transformation with the advent of immunotherapy, offering renewed hope and…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry grapples with an intractable challenge: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, discussions surrounding drug pricing often commence and conclude with the enigmatic "list…
Read More
